IONS Insider Trading Activity and SEC Form 4 Filings
IONS insider trading summary
Over the past 12 months, insiders at Ionis Pharmaceuticals Inc (IONS) reported 90 sales worth $93.0M by 18 insiders and no open-market purchases on SEC Form 4. Net insider selling was $93.0M.
Latest IONS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 16, 2026 | Eric Swayze | EVP Research | Sell | $2K (53 @ $43.54) |
| Oct 16, 2026 | Shannon L. Devers | EVP, Chief Human Resources Ofc | Sell | $59K (1,357 @ $43.54) |
| Jul 7, 2026 | Holly B. Kordasiewicz | EVP, Chief Development Officer | Sell | $31K (362 @ $84.30) |
| Jul 7, 2026 | C Frank Bennett | EVP, Chief Scientific Officer | Sell | $463K (5,536 @ $83.58) |
| Jul 7, 2026 | Allene M. Diaz | Director | Sell | $864K (10,111 @ $85.42) |
| Jul 7, 2026 | C Frank Bennett | EVP, Chief Scientific Officer | Sell | $1.3M (15,000 @ $85.46) |
| Jul 1, 2026 | Joseph Klein III | Director | Sell | $8K (99 @ $79.45) |
| Jul 1, 2026 | Joseph Klein III | Director | Sell | $903K (11,419 @ $79.04) |
| Jun 26, 2026 | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | Sell | $2.1M (26,000 @ $81.05) |
| Jun 26, 2026 | Patrick R. O'Neil | EVP CLO & General Counsel | Sell | $246K (3,069 @ $80.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.